Authors: McGuinness, Greer
Kim, Yeonsoo
Title: Sulforaphane treatment for autism spectrum disorder
Other Titles: a systematic review
Language (ISO): en
Abstract: Autism Spectrum Disorder (ASD) is defined as a neurodevelopmental condition characterized by social communication impairment, delayed development, social function deficit, and repetitive behaviors. The Center for Disease Control reports an increase in ASD diagnosis rates every year. This systematic review evaluated the use of sulforaphane (SFN) therapy as a potential treatment option for individuals with ASD. PubMed.gov, PubMed Central, Natural Medicines, BoardVitals, Google Scholar and Medline were searched for studies measuring the effects of SFN on behavior and cognitive function. All five clinical trials included in this systematic review showed a significant positive correlation between SFN use and ASD behavior and cognitive function. The current evidence shows with minimal side effects observed, SFN appears to be a safe and effective treatment option for treating ASD.
Subject Headings: Sulforaphane
Autism Spectrum Disorder
Glucosinolates
Treatment
CAM
URI: http://hdl.handle.net/2003/39908
http://dx.doi.org/10.17877/DE290R-21798
Publishers Link: https://www.excli.de/index.php/excli/article/view/2487
Issue Date: 2020-06-26
Rights link: https://creativecommons.org/licenses/by/4.0/
Provenance: IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund
Citation: McGuinness, G., & Kim, Y. (2020). Sulforaphane treatment for autism spectrum disorder: A systematic review. EXCLI Journal, 19, 892-903. https://doi.org/10.17179/excli2020-2487
Appears in Collections:Review Articles 2020

Files in This Item:
File Description SizeFormat 
excli2020-2487.pdfDNB159.81 kBAdobe PDFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons